Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Boehringer Ingelheim
Scientific Title
A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours